Abstract 15351: Significant Differential Metabolic Effects of Rosuvastatin and Pravastatin in Hypercholesterolemic Patients
Background: Statins have different effects on the rate of onset of new diabetes in large scale clinical studies. We hypothesized that rosuvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.
Methods: This was a randomized, single-blind, placebo-controlled, and parallel study. Age, sex, and body mass index were matched. All patients were recommended low fat diet. Each fifty-four patients were given placebo, rosuvastatin 10 mg, and pravastatin 40 mg, respectively daily during a 2 month treatment period.
Results: No significant differences between baseline values were noted in any of the parameters measured. Placebo significantly reduced total cholesterol, LDL cholesterol, and HDL cholesterol levels, however, did not significantly change insulin, plasma adiponectin levels, HbA1c, and insulin sensitivity (determined by QUICKI) relative to baseline measurements. Rosuvastatin and pravastatin therapy significantly changed lipoprotein levels and improved flow-mediated dilation after 2 months when compared with baseline (P<0.001) or placebo treatment (P<0.001 by ANOVA). When compared with pravastatin, rosuvastatin significantly decreased total cholesterol, LDL cholesterol, and Apo B levels (P<0.001). Rosuvastatin therapy significantly increased insulin levels (mean % changes; 28%, P=0.020) and HbA1c (1%, P=0.038) and decreased plasma adiponectin levels (9%, P=0.017) and insulin sensitivity as assessed by QUICKI (2%, P=0.032) when compared with baseline. By contrast, pravastatin therapy significantly decreased insulin levels (8%, P=0.048) and HbA1c (1%, P=0.019) but significantly increased plasma adiponectin levels (36%, P=0.001) and insulin sensitivity (3%, P=0.005) when compared with baseline. In addition, these effects of rosuvastatin were significant when compared with pravastatin (P=0.002 for insulin levels by ANOVA on Ranks, P=0.010 for HbA1c, P=0.003 for adiponectin, and P=0.003 for QUICKI by ANOVA).
Conclusions: Rosuvastatin and pravastatin therapy showed significant changes in lipoprotein and endothelium-dependent dilation, however, rosuvastatin and pravastatin therapy had differential metabolic effects in hypercholesterolemic patients.
- © 2010 by American Heart Association, Inc.